Key Targets for metabolic Treatments: GLP1 & GIP

Obesity has become a major public health crisis worldwide, and its prevalence has been increasing. GLP-1 receptor agonists (GLP-1RAs) offer significant benefits not only for blood sugar control but also for treating obesity and related metabolic disorders. These therapies gained widespread attention in 2023, achieving remarkable success and revitalizing interest in obesity treatments and GLP-1 therapies worldwide.
GLP-1 (Glucagon-like peptide-1) is an incretin hormone secreted by intestinal L cells. It is an activator of the receptor GLP-1R in a glucose-dependent manner to enhance insulin release and reduce glucagon secretion, thereby lowering blood sugar levels and resulting in weight reduction.
GLP-1R Agonists: An agonist is any natural or synthetic substance that mimics the action of a natural ligand and binds to a specific receptor and initiates the response. The GLP-1 receptor agonists work by activating GLP-1R and are primarily used in the treatment of T2D and obesity.
To support research in the treatment of Type 2 Diabetes and Obesity, we at BTL Biotechno Labs Pvt. Ltd. are proud to offer a comprehensive range of GLP-1 and related products. Our offerings include, but are not limited to, GLP-1(7-36) amide acetate, GLP-1(7-37), Exendin-4, Exendin (9-39) amide, Dulaglutide, CD26/Dipeptidyl Peptidase 4 Protein (Human, HEK293), GLP1R Protein (Human, HEK293, Fc), GLP-1 Antibody, GLP-1 -Lys(biotinyl) amide Peptide, GLP-2 Peptide, GLP-1R Antibody, Conjugated GLP-1R Antibodies (Biotin, FITC, HRP), GLP-1R ELISA Kit, and many more.
For more details, please connect with us at info@biotechnolabs.com